Phase 1 H3 K27M Clinical Trials
7 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–7 of 7 trials
Recruiting
Phase 1
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-Mutant
Ann & Robert H Lurie Children's Hospital of Chicago36 enrolled3 locationsNCT04943848
Recruiting
Phase 1
FUS Etoposide for DMG
Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-Mutant
Columbia University10 enrolled1 locationNCT05762419
Recruiting
Phase 1
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
Central Nervous System NeoplasmsGlioblastomaHigh Grade Glioma+4 more
St. Jude Children's Research Hospital48 enrolled1 locationNCT05835687
Recruiting
Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Central Nervous System NeoplasmsGlioblastomaOligodendroglioma+20 more
Jazz Pharmaceuticals102 enrolled1 locationNCT04541082
Recruiting
Phase 1Phase 2
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
Glioblastoma MultiformeOligodendrogliomaDiffuse Intrinsic Pontine Glioma+5 more
University of Miami20 enrolled1 locationNCT05956821
Recruiting
Phase 1
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
Diffuse Midline Glioma, H3 K27M-MutantRecurrent High Grade Glioma
OX2 Therapeutics24 enrolled1 locationNCT06305910
Recruiting
Phase 1
CAR T Cells to Target GD2 for DMG
Diffuse Midline Glioma, H3 K27M-Mutant
University College, London12 enrolled1 locationNCT05544526